Eli Lilly and Company

Milestones as listed on lilly.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Leadership as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on lilly.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on lilly.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Eli Lilly and Company: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 6 Oct 2026.

Clinical trials 224 in our ClinicalTrials.gov registers · 11 in the EU register

Showing 10 of 224, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 1 registry name

Drugs in these trials 96 compounds

EU trials register (CTIS) 11 authorised or ongoing

• A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication2025-522362-78-00 · Phase IV · Ongoing
• J2A-MC-GZGY: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes2025-524811-35-00 · Phase III · Authorised
• A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA2026-525574-19-00 · Phase I · Authorised
• J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.2025-523258-15-00 · Phase II · Ongoing
• J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.2025-522855-25-00 · Phase III · Ongoing
• J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)2026-525480-41-00 · Phase II · Ongoing
• J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease2025-524112-11-00 · Phase II · Ongoing
• A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers2025-523601-16-00 · Phase I · Authorised

Recent approvals

• InluriyoEMA · imlunestrant · 9 Jan 2026
• ZepboundFDA · Tirzepatide · 8 Nov 2023 · New Drug (NDA)

Medicine shortages 8 in the FDA list

• Insulin Lispro Protamine and Insulin Lispro InjectionUS (FDA) · resolved · updated 1 Sep 2026
• Insulin Glargine-aglr InjectionUS (FDA) · resolved · updated 1 Sep 2026
• Insulin Lispro InjectionUS (FDA) · resolved · updated 1 Sep 2026
• Mirikizumab-mrkz InjectionUS (FDA) · resolved · updated 22 Dec 2025
• Lasmiditan Succinate TabletUS (FDA) · resolved · updated 3 Nov 2025
• Insulin Lispro-aabc InjectionUS (FDA) · resolved · updated 24 Oct 2025
• Insulin Glargine InjectionUS (FDA) · resolved · updated 24 Oct 2025
• Pemetrexed Disodium InjectionUS (FDA) · resolved · updated 16 Oct 2025

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 29 of its medicines · 28 current

• Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)NICE TA1168 · Terminated (no company submission) · 18 Jun 2026
• Mirikizumab for previously treated moderately to severely active Crohn's diseaseNICE TA1080 · Optimised · 10 Jul 2025
• Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerNICE TA1042 · Optimised · 19 Feb 2025
• Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and overNICE TA1038 · Optimised · 12 Feb 2025
• Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and overNICE TA1039 · Recommended · 12 Feb 2025
• Tirzepatide for managing overweight and obesityNICE TA1026 · Optimised · 23 Dec 2024
• Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and overNICE TA986 · Optimised · 10 Jul 2024
• Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)NICE TA982 · Terminated (no company submission) · 13 Jun 2024

Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Eli Lilly and Company): founded 1901, headquarters Indianapolis, website lilly.com. Wikidata Q632240 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here Eli Lilly and Company; Eli Lilly & Co.; Eli Lilly Nederland B.V.; Eli Lilly and Company Limited; Eli Lilly Kinsale Limited; ELI LILLY AND CO and 3 more. Spot a wrong match? Tell us.

From the annual reports Eli Lilly and Company files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.

R&D is shown as tagged in the filing, which for this company can exclude acquired in-process R&D. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 4 active in the CRO register · 1 dissolved not shown

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Eli Lilly and Company as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.